Physician profile
Prem Kumar
NPI 1962571299
$4,710.03
in general payments reported to CMS, 2019-2025
26 companies · $401 in 2025
The $401 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $544 · 2021: $1,271 · 2022: $677 · 2023: $555 · 2024: $526 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,483.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $952.24 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $677.57 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $462.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $421.01 | 2020-2024 | Farxiga |
| Glaxosmithkline, LLC. | $375.31 | 2019-2024 | Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $302.24 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $280.76 | 2019-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $265.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| United Therapeutics Corporation | $149.17 | 2019-2021 | |
| Amgen INC. | $125.00 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.91 | 2019-2025 | Lifevest |
| Janssen Scientific Affairs, LLC | $92.50 | 2024 | Xarelto |
| Boston Scientific Corporation | $75.92 | 2019-2025 | Watchman |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.27 | 2023-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $68.02 | 2020-2025 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.49 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $49.82 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.95 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $27.78 | 2019 | |
| Heartflow, INC. | $25.80 | 2021 | |
| Exact Sciences Corporation | $20.50 | 2025 | Cologuard Collection Kit |
| Lexicon Pharmaceuticals, INC. | $19.23 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $18.39 | 2024 | Opsumit |
| Preventice Services, LLC | $17.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.61 | 2019 | |
| Circassia INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prem Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.